PharmaResources (Shanghai) Co. Ltd. A - Asset Resilience Ratio
PharmaResources (Shanghai) Co. Ltd. A (301230) has an Asset Resilience Ratio of 16.35% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 301230 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how PharmaResources (Shanghai) Co. Ltd. A's Asset Resilience Ratio has changed over time. See debt-free asset ratio of PharmaResources (Shanghai) Co. Ltd. A to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down PharmaResources (Shanghai) Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 301230 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥215.15 Million | 16.35% |
| Total Liquid Assets | CN¥215.15 Million | 16.35% |
Asset Resilience Insights
- Good Liquidity Position: PharmaResources (Shanghai) Co. Ltd. A maintains a healthy 16.35% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
PharmaResources (Shanghai) Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare PharmaResources (Shanghai) Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for PharmaResources (Shanghai) Co. Ltd. A (2021–2025)
The table below shows the annual Asset Resilience Ratio data for PharmaResources (Shanghai) Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.95% | CN¥248.98 Million ≈ $36.43 Million |
CN¥1.31 Billion ≈ $192.29 Million |
-0.18pp |
| 2024-12-31 | 19.13% | CN¥251.77 Million ≈ $36.84 Million |
CN¥1.32 Billion ≈ $192.63 Million |
-3.79pp |
| 2023-12-31 | 22.92% | CN¥340.79 Million ≈ $49.87 Million |
CN¥1.49 Billion ≈ $217.62 Million |
+22.10pp |
| 2022-12-31 | 0.82% | CN¥10.65 Million ≈ $1.56 Million |
CN¥1.30 Billion ≈ $190.42 Million |
+0.75pp |
| 2021-12-31 | 0.07% | CN¥397.68K ≈ $58.19K |
CN¥557.81 Million ≈ $81.62 Million |
-- |
About PharmaResources (Shanghai) Co. Ltd. A
PharmaResources (Shanghai) Co., Ltd. engages in new drug research, development, and commercial production in China. It offers small molecule drug CRO, CDMO, and CMO. The company also involved in drug discovery, research, and development of pharmaceutical processes; and customized and commercial production of APIs, and key intermediates. It serves global pharmaceutical and biotechnology companies.… Read more